$BMY Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $1.35 down -17.18% YoY
• Reported revenue of $13.07B up 7.12% YoY
• Bristol Myers Squibb raised 2026 non-GAAP revenue guidance to approximately $49.75B to $50.25B and updated non-GAAP EPS guidance to $6.35 to $6.55, including -$0.6 from Acquired IPRD charges and licensing income.